Arena Pharmaceuticals (FRA:RN3N) Current Accrued Expense : €35.22 Mil (As of Dec. 2021)

View and export this data going back to 2000. Start your Free Trial

What is Arena Pharmaceuticals Current Accrued Expense?

Arena Pharmaceuticals's Current Accrued Expense for the quarter that ended in Dec. 2021 was €35.22 Mil.

Arena Pharmaceuticals's quarterly Current Accrued Expense declined from Jun. 2021 (€38.09 Mil) to Sep. 2021 (€21.81 Mil) but then increased from Sep. 2021 (€21.81 Mil) to Dec. 2021 (€35.22 Mil).

Arena Pharmaceuticals's annual Current Accrued Expense increased from Dec. 2019 (€18.70 Mil) to Dec. 2020 (€18.76 Mil) and increased from Dec. 2020 (€18.76 Mil) to Dec. 2021 (€35.22 Mil).

Arena Pharmaceuticals Current Accrued Expense Historical Data

The historical data trend for Arena Pharmaceuticals's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arena Pharmaceuticals Current Accrued Expense Chart

Arena Pharmaceuticals Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Current Accrued Expense

Get a 7-Day Free Trial

27.69

10.39

18.70

18.76

35.22

Arena Pharmaceuticals Quarterly Data
	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21
Current Accrued Expense	Get a 7-Day Free Trial															18.76	22.37	38.09	21.81	35.22

Arena Pharmaceuticals Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Arena Pharmaceuticals Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Arena Pharmaceuticals's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Arena Pharmaceuticals (FRA:RN3N) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arena Pharmaceuticals Inc (FRA:RN3N) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

136 Heber Avenue, Suite 204, Park City, UT, USA, 84060

Website

https://www.arenapharm.com

Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain.

Arena Pharmaceuticals (FRA:RN3N) Headlines

No Headlines